BriaCell Therapeutics Corp.āđāļāļīāđāļĄāļāļķāđāļ
BriaCell - Update on Breast Cancer ðïļ
-Shares of BriaCell Therapeutics Corp. BCTX, 111.64% more than doubled Wednesday on heavy volume, after the biotechnology company provided upbeat update on its breast cancer treatment.
-The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of "eye-bulging" tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials.
-
-The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of "eye-bulging" tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials.
-
āļāļģāļāļģāļāļąāļāļŠāļīāļāļāļīāđāļāļ§āļēāļĄāļĢāļąāļāļāļīāļāļāļāļ
āļāđāļāļĄāļđāļĨāđāļĨāļ°āļāļāļāļ§āļēāļĄāđāļĄāđāđāļāđāļĄāļĩāļ§āļąāļāļāļļāļāļĢāļ°āļŠāļāļāđāđāļāļ·āđāļāļāđāļāđāļŦāđāđāļāļīāļāļāļīāļāļāļĢāļĢāļĄāļāļēāļāļāļēāļĢāđāļāļīāļ, āļāļēāļĢāļĨāļāļāļļāļ, āļāļēāļĢāļāļ·āđāļāļāļēāļĒ, āļāđāļāđāļŠāļāļāđāļāļ° āļŦāļĢāļ·āļāļāļģāđāļāļ°āļāļģāļāļĢāļ°āđāļ āļāļāļ·āđāļ āđ āļāļĩāđāđāļŦāđāļŦāļĢāļ·āļāļĢāļąāļāļĢāļāļāđāļāļĒ TradingView āļāđāļēāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļĩāđ āļāđāļāļāļģāļŦāļāļāļāļēāļĢāđāļāđāļāļēāļ